ReP USP - Resultado da busca

Filtros : "FERREIRA, ANA MARIA DA COSTA" "Frontiers in Molecular Biosciences" Removidos: "Universidade Federal de Juiz de Fora (UFJF)" "Centro de Desenvolvimento da Tecnologia Nuclear - Laboratório de Física Aplicada, Belo Horizonte, MG, Brasil" "Research Centre IRCCS San Raffaele Pisana, Rome, Italy" "PEROTTI, GUSTAVO FRIGI" "PATENTE" Limpar

Filtros

Artigo de periodico-carta/editorial
Design, synthesis, and preclinical testing of innovative anti-cancer compounds With a high level of selectivity of action and low toxicity [Editorial] (2022)
Ferreira, Ana Maria da Costa ; Stock, Regine Schneider; Aiello, Francesca
Fonte: Frontiers in Molecular Biosciences. Unidade: IQ
Assuntos: ANTINEOPLÁSICOS, METABOLÔMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Ana Maria da Costa e STOCK, Regine Schneider e AIELLO, Francesca. Design, synthesis, and preclinical testing of innovative anti-cancer compounds With a high level of selectivity of action and low toxicity [Editorial]. Frontiers in Molecular Biosciences. Lausanne: Instituto de Química, Universidade de São Paulo. Disponível em: https://doi.org/10.3389/fmolb.2022.859821. Acesso em: 29 jun. 2024. , 2022
APA
Ferreira, A. M. da C., Stock, R. S., & Aiello, F. (2022). Design, synthesis, and preclinical testing of innovative anti-cancer compounds With a high level of selectivity of action and low toxicity [Editorial]. Frontiers in Molecular Biosciences. Lausanne: Instituto de Química, Universidade de São Paulo. doi:10.3389/fmolb.2022.859821
NLM
Ferreira AM da C, Stock RS, Aiello F. Design, synthesis, and preclinical testing of innovative anti-cancer compounds With a high level of selectivity of action and low toxicity [Editorial] [Internet]. Frontiers in Molecular Biosciences. 2022 ; 9 1-2 art. 859821.[citado 2024 jun. 29 ] Available from: https://doi.org/10.3389/fmolb.2022.859821
Vancouver
Ferreira AM da C, Stock RS, Aiello F. Design, synthesis, and preclinical testing of innovative anti-cancer compounds With a high level of selectivity of action and low toxicity [Editorial] [Internet]. Frontiers in Molecular Biosciences. 2022 ; 9 1-2 art. 859821.[citado 2024 jun. 29 ] Available from: https://doi.org/10.3389/fmolb.2022.859821
Artigo de periodico
Anticancer compounds based on isatin-derivatives: strategies to ameliorate selectivity and efficiency (2021)
Paiva, Raphael Enoque Ferraz de; Vieira, Eduardo Guimarães ; Silva, Daniel Rodrigues da ; Wegermann, Camila Anchau ; Ferreira, Ana Maria da Costa
Fonte: Frontiers in Molecular Biosciences. Unidade: IQ
Assuntos: ANTINEOPLÁSICOS, ALCALOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PAIVA, Raphael Enoque Ferraz de et al. Anticancer compounds based on isatin-derivatives: strategies to ameliorate selectivity and efficiency. Frontiers in Molecular Biosciences, v. 7, p. 1-24 art. 627272, 2021Tradução . . Disponível em: https://doi.org/10.3389/fmolb.2020.627272. Acesso em: 29 jun. 2024.
APA
Paiva, R. E. F. de, Vieira, E. G., Silva, D. R. da, Wegermann, C. A., & Ferreira, A. M. da C. (2021). Anticancer compounds based on isatin-derivatives: strategies to ameliorate selectivity and efficiency. Frontiers in Molecular Biosciences, 7, 1-24 art. 627272. doi:10.3389/fmolb.2020.627272
NLM
Paiva REF de, Vieira EG, Silva DR da, Wegermann CA, Ferreira AM da C. Anticancer compounds based on isatin-derivatives: strategies to ameliorate selectivity and efficiency [Internet]. Frontiers in Molecular Biosciences. 2021 ; 7 1-24 art. 627272.[citado 2024 jun. 29 ] Available from: https://doi.org/10.3389/fmolb.2020.627272
Vancouver
Paiva REF de, Vieira EG, Silva DR da, Wegermann CA, Ferreira AM da C. Anticancer compounds based on isatin-derivatives: strategies to ameliorate selectivity and efficiency [Internet]. Frontiers in Molecular Biosciences. 2021 ; 7 1-24 art. 627272.[citado 2024 jun. 29 ] Available from: https://doi.org/10.3389/fmolb.2020.627272

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo 2012 - 2024